← Bicara Therapeutics Inc. (BCAX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Bicara Therapeutics Inc. (BCAX)
Pharmaceutical Preparations · market cap $1.4B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
1
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Bicara Therapeutics (BCAX) is a clinical-stage pharmaceutical company with a single disclosed asset, ficerafusp alfa, currently in Phase 3 development for metastatic head and neck squamous cell carcinoma (mHNSCC). With a $1.82B market cap, $323.5M in cash, and roughly 26 months of runway, the company is a pure-play binary bet on one trial readout. No revenue has been reported and the mechanism of action for ficerafusp alfa is not disclosed in available facts.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2027-06-30 (est.)Trial Startimp 4/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Ficerafusp alfa | Phase 3 | Metastatic Head and Neck Squamous Cell Carcinoma |
Price & technical context
3-month
-37.2%
6-month
-11.2%
12-month
+15.3%
52-wk range
$13.93–$30.40
vs 50-day MA
-23.7%
vs 200-day MA
-14.6%
Realized vol
56.1%
Max drawdown
-67.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BCAX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.